Targeting the eicosanoid pathway in non-small-cell lung cancer

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 6, 2009, Pages 675-688

  Horn, Leora ^a   Backlund, Michael ^a   Johnson, David H ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cyclooxygenase 2; Eicosanoids; Non small cell lung cancer; Prostaglandin E2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; ICOSANOID; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; ONO AE3 208; PACLITAXEL; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; ROSIGLITAZONE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN; ZILEUTON;

ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPATITIS; HUMAN; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG RESECTION; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHENOTYPE; PNEUMONIA; PROTEIN EXPRESSION; QUALITY OF LIFE; RASH; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; UPREGULATION; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EICOSANOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; UP-REGULATION;

EID: 67649607484     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902915567     Document Type: Review

References (101)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98 (Pubitemid 34438899)
3. Forgacs E, Zochbauer-Muller S, Olah E, et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 2001;7:6-13 (Pubitemid 32591661)
4. Brown JR, Dubois RN. Cyclooxygenase a target in lung cancer. Clin Cancer Res 2004;10(Suppl.):4266-4269 (Pubitemid 38812460)
5. Krysan K, Reckamp KL, Sharma S, et al. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006;6:209-220 (Pubitemid 43796639)
6. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-122 (Pubitemid 41820645)
7. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-1610 (Pubitemid 36554582)
8. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764 (Pubitemid 28405625)
9. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-2645 (Pubitemid 32011609)
10. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001 (Pubitemid 28521147)
11. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-443 (Pubitemid 34183896)
12. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-867 (Pubitemid 32708722)
13. Laga AC, Zander DS, Cagle PT. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch Pathol Lab Med 2005;129:1113-1117 (Pubitemid 41244809)
14. Josephy PD, Chiu AL, Eling TE. Prostaglandin H synthase-dependent mutagenic activation of benzidine in a Salmonella typhimurium Ames tester strain possessing elevated N-acetyltransferase levels. Cancer Res 1989;49:853-856 (Pubitemid 19064335)
15. Kelley DJ, Mestre JR, Subbaramaiah K, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997;18:795-799 (Pubitemid 28132470)
16. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65:664-670
17. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311 (Pubitemid 30151999)
18. Goldman AP, Williams CS, Sheng H, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998;19:2195-2199 (Pubitemid 29010262)
19. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011 (Pubitemid 30305099)
20. Hida T, Kozaki K-I, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002;8:2443-2447
21. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-2259 (Pubitemid 27203783)
22. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth [see comments]. J Clin Invest 2000;105:1589-1594 (Pubitemid 30390309)
23. Kim ES, Hong WK, Lee JJ, et al. A randomized double-blind study of the biological effects of celecoxib as a chemopreventive agent in current and former smokers. J Clin Oncol 2008;26:1501
24. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
25. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142 (Pubitemid 47010839)
26. Gridelli C, Gallo C, Ceribelli A, et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007;8:500-512 (Pubitemid 46805905)
27. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756-1764
28. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy. Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855
29. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007;357:1841-1854
30. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-813 (Pubitemid 26057100)
31. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998;19:1393-1400 (Pubitemid 28409837)
32. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024 (Pubitemid 46606280)
33. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218 (Pubitemid 32591438)
34. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005 (Pubitemid 29233213)
35. Gadgeel SM, Wozniak A, Ruckdeschel JC, et al. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1293-1300
36. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959 (Pubitemid 33010342)
37. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597 (Pubitemid 41079796)
38. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103 (Pubitemid 30324363)
39. Burton JD, Badine E, El-Sayah D, et al. Update of a phase I/II trial of carboplatin/ gemcitabine plus escalating doses of celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22:7339
40. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-6763 (Pubitemid 39383023)
41. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-2650 (Pubitemid 46606306)
42. Pisters KM, Kris MG, Gralla RJ, et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993;11:1757-1762 (Pubitemid 23277329)
43. Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen- activated protein kinase pathways. J Biol Chem 2000;275:14838-14845 (Pubitemid 30337196)
44. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-4197 (Pubitemid 40791585)
45. Milella M, Ceribelli A, Gelibter A, et al. Celecoxib combined with fixed dose-rate Gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23:7324
46. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362 (Pubitemid 30415821)
47. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-6640 (Pubitemid 41339004)
48. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 1970;225:600-604
49. Seyberth HW, Sweetman BJ, Frolich JC, et al. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976;11:381-397
50. Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE(2) by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE(2) synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-275
51. Gross ND, Boyle JO, Morrow JD, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-6093 (Pubitemid 41170341)
52. Nugent FW, Mertens WC, Graziano S, et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 2005;48:267-273 (Pubitemid 40501817)
53. Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008;3:1454-1459
54. Lorenz M, Slaughter HS, Wescott DM, et al. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol 1999;27:1494-1502 (Pubitemid 29458423)
55. Gasparini G, Meo S, Comella G, et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 2005;11:209-216 (Pubitemid 44698809)
56. Esteban E, Gonzalez de Sande L, Fernandez Y, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003;14:1640-1647 (Pubitemid 37455813)
57. Aisner J. Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III? Cancer J 2005;11:201-203
58. Lilenbaum R, Socinski MA, Altorki NK, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/ irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006;24:4825-4832 (Pubitemid 46630908)
59. Gradilone A, Silvestri I, Scarpa S, et al. Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. Oncol Rep 2007;17:823-828
60. Gradilone A, Pulcinelli FM, Lotti LV, et al. Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications. J Clin Oncol 2007;25:4318-4320 (Pubitemid 47548578)
61. Tian Q, Zhang J, Tan TM, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 2005;22:1837-1853 (Pubitemid 41504337)
62. Argiris A, Kut V, Luong L, et al. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Invest New Drugs 2006;24:203-212 (Pubitemid 43723897)
63. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454
64. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829 (Pubitemid 351757205)
65. Krysan K, Lee JM, Dohadwala M, et al. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 2008;3:107-110 (Pubitemid 351323182)
66. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-9462 (Pubitemid 41508014)
67. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-950 (Pubitemid 43165962)
68. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-20812 (Pubitemid 37413056)
69. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002;277:50828-50833 (Pubitemid 36042248)
70. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 2006;66:5338-5345
71. Reckamp KL, Krysan K, Morrow JD, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006;12:3381-3388 (Pubitemid 43910883)
72. Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008;14:2088-2094 (Pubitemid 351551120)
73. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005;23:4719-4725 (Pubitemid 46224075)
74. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
75. Gadgeel SM, Ruckdeschel JC, Heath EI, et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:299-305 (Pubitemid 47181712)
76. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537 (Pubitemid 41540110)
77. Agarwala A, Fisher W, Bruetman D, et al. Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2008;3:374-379
78. O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007;25:3266-3273 (Pubitemid 47325611)
79. Hirsch FR, Dziadziuszko R, Thatcher N, et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008;112:1114-1121 (Pubitemid 351304597)
80. Samuelsson B, Morgenstern R, Jakobsson P-J. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 2007;59:207-224 (Pubitemid 47481434)
81. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7:2669-2674 (Pubitemid 32911370)
82. Kim WI, Choi KA, Do HS, et al. Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library. BMB Rep 2008;41:808-813
83. Abdulhameed MDM, Hamza A, Liu J, et al. Human microsomal prostaglandin E synthase-1 (mPGES-1) binding with inhibitors and the quantitative structure-activity correlation. J Chem Inf Model 2008;48:179-185 (Pubitemid 351271063)
84. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007;67:5587-5593 (Pubitemid 46984987)
85. Huang G, Eisenberg R, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008;68:5040-5048
86. Hughes D, Otani T, Yang P, et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res 2008;1:241-249
87. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-3223 (Pubitemid 40223783)
88. Ding Y, Tong M, Liu S, et al. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72 (Pubitemid 40207700)
89. Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008;40:789-793 (Pubitemid 351748871)
90. Coggins KG, Coffman TM, Koller BH. The Hippocratic finger points the blame at PGE2. Nat Genet 2008;40:691-692 (Pubitemid 351748881)
91. Hazra S, Batra RK, Tai HH, et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-1720 (Pubitemid 47010924)
92. Dubinett SM, Mao JT, Hazra S. Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase. Cancer Prev Res 2008;1:223-225
93. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-1481 (Pubitemid 46733074)
94. Girnun GD, Naseri E, Vafai SB, et al. Synergy between PPAR[gamma] ligands and platinum-based drugs in cancer. Cancer Cell 2007;11:395-406 (Pubitemid 46670076)
95. Kapoor M, Kojima F, Qian M, et al. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 2007;282:5356-5366 (Pubitemid 47093760)
96. Girnun GD, Chen L, Silvaggi J, et al. Regression of drug-resistant lung cancer the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008;14:6478-6486
97. Bos CL, Richel DJ, Ritsema T, et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004;36:1187-1205 (Pubitemid 38515660)
98. Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006;66:2923-2927
99. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-9672 (Pubitemid 44623666)
100. Backlund MG, Amann JM, Johnson DH. Novel strategies for the treatment of lung cancer: modulation of eicosanoids. J Clin Oncol 2008;26:825-827
101. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080 (Pubitemid 40365348)